Patient “Cost-Support” Fax Can Be a TCPA Advertisement Even with Informational Content

1. Introduction

In S.A.S.B. CORP v. Johnson & Johnson Health Care Systems Inc. (3d Cir. Aug. 7, 2026), S.A.S.B. Corp. (“SASB”), a Florida pharmacy operating as Okeechobee Discount Drugs, brought a putative class action under the Telephone Consumer Protection Act (“TCPA”) against two Johnson & Johnson subsidiaries: Janssen Pharmaceuticals, Inc. (“J-Pharm”) and Johnson & Johnson Health Care Systems Inc. (“J-Care”).

SASB alleged the defendants sent an unsolicited two-page fax touting Janssen CarePath—described as a patient support program—highlighting “savings options” and “cost support” for the prescription drug Xarelto. The District of New Jersey dismissed on the ground that the fax was not an “advertisement” under the TCPA. The Third Circuit reversed, holding that SASB plausibly alleged the fax was an unsolicited advertisement and also plausibly alleged the defendants sent it, while rejecting demands for heightened pleading about sender identity and rejecting an argument that collective pleading failed Rule 8 in the circumstances.

2. Summary of the Opinion

  • Advertisement: The court held a reasonable factfinder could view the two-page fax as material “advertising the commercial availability or quality” of Xarelto by emphasizing affordability through Janssen CarePath’s cost-support and savings options, and that such promotion plausibly had “profit as an aim.”
  • Informational content does not immunize: Even if the second page (uses/side effects) was informational “in isolation,” the defendants could not avoid TCPA exposure by appending an informational page to an unsolicited promotional fax.
  • Sender plausibility: SASB plausibly alleged the defendants sent the fax where the fax spoke in defendants’ voice, used their branding, and appeared to merge personalized patient data; the court refused to impose a requirement to plead fax logs/cover sheets.
  • Rule 8 notice / collective pleading: Pleading that “Defendants” collectively sent the fax provided adequate notice where the missing allocation of responsibility was “peculiarly within the defendant’s possession” and discovery was the proper vehicle to clarify roles.

3. Analysis

3.1. Precedents Cited

TCPA “Advertisement” Framework in the Third Circuit

  • Robert W. Mauthe MD PC v. Millenium Health LLC ("Millenium"): The court relied on Millenium for its two-part test: a fax must (1) “promote goods or services to be bought or sold” and (2) “have profit as an aim,” both judged objectively. Millenium also recognized that “coupons” are commonly associated with advertising—an analogy the court used to treat “cost support” and “savings options” as promotion by price/affordability.
  • Robert Mauthe, M.D., P.C. v. Optum Inc. ("Optum"): The opinion cited Optum for the core definition that the fax must “promote goods or services to be bought or sold,” and for the concept that a fax can aim to influence a third party’s purchasing decisions. The panel distinguished third-party influence as unnecessary here because the fax spoke to the patient as anticipated purchaser.
  • Fischbein v. Olson Rsch. Grp., Inc.: Cited via Millenium for the “profit as an aim” requirement, reinforcing that promotional content need not quote a price or contain an explicit “buy now” if it functions to drive revenue.

“Common Sense” Reading and Cross-Circuit Guidance

  • Chesbro v. Best Buy Stores, L.P.: Borrowed for the admonition to apply “a measure of common sense” in identifying advertisements—supporting the Third Circuit’s rejection of a hyper-literal focus on “support/help/explore” as non-commercial when the context urged product affordability.
  • Smith v. First Hosp. Lab'ys, Inc.: Used to validate the idea that messaging “urg[ing] the purchase” by emphasizing affordability can be advertising even if framed as assistance; the Third Circuit treated CarePath’s cost-support language as plausibly functioning in that manner.
  • Sandusky Wellness Center, LLC v. Medco Health Solutions, Inc.: Cited to acknowledge that informational communications can exist under the TCPA. The Third Circuit accepted that the second page looked informational “in isolation,” but limited Sandusky’s relevance by insisting the fax must be evaluated as a whole and by rejecting “informational add-on” insulation.

Pleading Standards and Notice

  • Bell Atl. Corp. v. Twombly: Provided the plausibility framework (“conceivable to plausible”) applied to both the advertisement issue and the “who sent the fax” issue.
  • Doe v. Princeton Univ.: Cited twice: first for the motion-to-dismiss lens (accept allegations as true), and second to stress that plausibility is “not akin to a probability requirement,” rejecting defendants’ attempt to force SASB to plead the most likely sender.
  • Klotz v. Celentano Stadtmauer & Walentowicz LLP: Cited for plenary review and the Rule 12(b)(6) standard.
  • Lincoln Ben. Life Co. v. AEI Life, LLC: Key to the Rule 8/collective pleading analysis: the court accepted incomplete allegations where details are “peculiarly within the defendant’s possession,” justifying discovery to determine “division of responsibility.”
  • Sheeran v. Blyth Shipholding S.A.: Defendants invoked it for the proposition that group pleading may fail to give notice; the Third Circuit rejected that move on these facts, finding both subsidiaries were sufficiently on notice.

3.2. Legal Reasoning

  1. Holistic, objective reading of the fax: The court refused to atomize the text into isolated non-commercial words (“support,” “explore,” “explain,” “help”). Context mattered: promises to “lower your out-of-pocket cost for Xarelto” can function as product promotion by price—akin to a discount offer.
  2. Affordability as promotion; profit aim as plausible: SASB’s pleaded price disparity ($400 for Xarelto vs. $20 for generic Warfarin) made it plausible that “cost support” was designed to shift demand toward Xarelto. From that, it was plausible the fax both promoted Xarelto and aimed at profit (increased sales or retention).
  3. No “informational attachment” safe harbor: Even accepting that side-effect and use information can be non-advertising, the court treated the two pages as a single communication, noting the second page ended by directing recipients to “Explore savings options.” The principle is functional: adding informative content does not negate promotional character where the overall message urges acquisition by highlighting financial assistance.
  4. Sender identity: plausibility, not proof: The court emphasized that at the pleading stage SASB need not produce fax logs or cover sheets. It was enough that the fax spoke as Janssen (“At Janssen, we…”), bore the Xarelto and CarePath branding, and appeared to use a targeted database. The defense theory (doctor likely sent it) went to probability and evidence, not plausibility—especially where SASB alleged time-zone facts undermining the “doctor as sender” inference.
  5. Collective pleading under Rule 8: The court held that alleging both subsidiaries sent the fax was sufficient notice given their corporate relationship and the likelihood that the “creating, authorizing, or transmitting” functions were internal and discoverable only through defendants’ records.

3.3. Impact

  • Expanded practical exposure for “patient support” marketing by fax: Pharmaceutical and healthcare entities using cost-assistance programs should expect that faxes emphasizing savings, affordability, or “cost support” can be treated as advertisements—even if framed as patient help or education.
  • No easy avoidance via mixed-content formatting: The decision discourages bundling promotional content with warnings or educational content to argue the overall fax is “informational.” Courts in the Third Circuit may examine the entire fax’s function, including calls to action like “Explore savings options.”
  • Pleading sender identity becomes less onerous: Plaintiffs may rely on branding, voice, and contextual indicators to plead who sent a fax without attaching technical transmission records—potentially increasing cases that survive motions to dismiss and proceed to discovery.
  • Group pleading more resilient where allocation is internal: Where multiple affiliated entities plausibly participated, alleging “Defendants” collectively may suffice until discovery clarifies roles, especially when the division of labor is within defendants’ exclusive knowledge.

4. Complex Concepts Simplified

“Unsolicited advertisement” (TCPA fax rule)
Under 47 U.S.C. § 227(b)(1)(C), it is generally unlawful to send an unsolicited fax that advertises goods or services. The TCPA defines “advertisement” broadly as material advertising the “commercial availability or quality” of goods or services (47 U.S.C. § 227(a)(5)).
“Promote goods or services to be bought or sold”
The fax does not need to say “buy now.” If it is reasonably read as encouraging purchase—here, by making Xarelto seem financially attainable—it can qualify.
“Profit as an aim”
The court looks for an objective commercial purpose. A message pushing affordability programs can still aim at profit by increasing sales volume or retaining customers.
Rule 12(b)(6) “plausibility”
At the motion-to-dismiss stage, the question is whether the plaintiff’s story is plausible—not whether it is proven or even most likely. Competing explanations (e.g., “the doctor sent it”) generally do not defeat plausibility.
Rule 8 notice pleading and “information uniquely in the defendant’s possession”
A plaintiff can proceed with less detail when the missing specifics (such as which affiliate authorized or transmitted the fax) are controlled by defendants and can be obtained through discovery.

5. Conclusion

The Third Circuit’s decision establishes that a fax promoting a drug’s affordability through a manufacturer-administered “patient support” or “cost support” program can constitute an “unsolicited advertisement” under the TCPA, even when paired with informational content like usage and side-effect warnings. The court also reinforced plaintiff-friendly pleading principles: sender identity can be plausibly alleged from branding and contextual cues without fax logs, and collective allegations against affiliated defendants can satisfy Rule 8 where internal responsibility is best clarified in discovery. In combination, these holdings lower dismissal-stage barriers in TCPA fax litigation involving healthcare marketing framed as assistance.